DeLorean Artificial Intelligence

DeLorean Artificial Intelligence, founded in 2019 by Severance "Sev" MacLaughlin, is a Palm Beach-based company specializing in predictive artificial intelligence solutions for healthcare and sales. The company's flagship product, Medical AI (MARTI), is designed to predict disease onset, progression, and optimal treatments for conditions such as Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Diabetes, and Cardiovascular Disease (CVD). MARTI analyzes medical records to forecast health events, identify high-risk patients, and provide personalized care recommendations. In September 2022, DeLorean AI announced that its Medical AI product became the first in the world to be biologically validated by third-party review, confirming the accuracy of its predictions through blood tests and hospitalization follow-ups.

The company's AI technology aims to improve healthcare outcomes while reducing costs. DeLorean AI claims to save USD 15,000 per ESRD patient, USD 14,500 per CKD patient, USD 2,800 per Diabetes patient, and USD 1,000 per CVD patient annually. As of February 2023, the company had processed records for over 45 million patients for select conditions. DeLorean AI operates on an "AI-as-a-service" model and reported annual revenues of USD 35 million in 2023. The company employs approximately 15 people across the US, with a focus on hiring in Florida, Texas, and Tennessee.

In addition to its healthcare offerings, DeLorean AI has developed Customer Relations Management AI (CRM AI), a product designed to predict sales outcomes and optimize sales processes. The company claims that clients using CRM AI have seen a 7% increase in sales. DeLorean AI's technology can integrate with various CRM platforms to provide real-time predictions on deal performance, win/loss probability, and recommended actions to improve sales outcomes.